查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1608029

人类胚胎干细胞市场：按类型、应用和最终用户划分 - 全球预测 2025-2030

Human Embryonic Stem Cells Market by Type (Pluripotent Stem Cells, Totipotent Stem Cells, Unipotent Stem Cells), Application (Regenerative Medicine, Stem Cell Biology Research, Tissue Engineering), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年，人类胚胎干细胞市值为8.4835亿美元，预计2024年将达到9.2043亿美元，复合年增长率为8.98%，预计2030年将达到15.4981亿美元。

人类胚胎干细胞（hESC）是一种源自早期人类胚胎的多功能细胞，可分化成任何细胞类型。其独特的特性对于再生医学、药物发现和发育生物学至关重要。对 hESC 的需求在于它们有可能彻底改变帕金森氏症、糖尿病和心臟病等疾病的治疗方法。这些细胞还可以应用于毒理学测试、基因研究和个人化医疗，以提供针对患者的治疗方法。最终用户包括专注于干细胞研究的研究机构、生物技术公司和临床研究组织。主要成长动力包括再生医学的进步、政府和私人对干细胞研究的资助增加，以及需要创新治疗解决方案的慢性疾病的增加。此外，人们对精准医疗日益增长的兴趣为使用 hESC 进行治疗提供了有利可图的机会。然而，围绕 hESC 来源的伦理问题和监管障碍构成了重大挑战。控制干细胞分化的技术限制以及基于 hESC 的治疗的高成本也阻碍了市场的成长。透过开发道德采购方法、增强分化技术和降低生产成本，有机会克服这些挑战并扩大 hESC 的接受和应用。这个市场还有潜力进行合作研究，以共用技术并提高公众对干细胞效用的认识。随着对先进治疗解决方案的需求不断增加，创新变得至关重要。重点领域包括改善细胞疗法的基因工程、扩大生产规模以实现更广泛的获取，以及改进生物资讯学以实现更好的疾病建模。随着相关人员解决伦理和监管问题、创建创新解决方案并适应个人化医疗和再生疗法不断变化的需求，hESC 市场充满活力，并有望实现显着成长。

主要市场统计
基准年[2023] 8.4835 亿美元
预计年份 [2024] 92043万美元
预测年份 [2030] 15.4981亿美元
复合年增长率（%） 8.98%

市场动态：揭示快速发展的人类胚胎干细胞市场的关键市场洞察

人类胚胎干细胞市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 遗传疾病迅速增加
    • 提高消费者对干细胞疗法在治疗疾病方面的效用的认识
    • 再生医学需求不断成长
  • 市场限制因素
    • 治疗费用上涨
  • 市场机会
    • 人类胚胎干细胞正在进行的研究活动
    • 干细胞治疗技术开发
  • 市场挑战
    • 严格的政府法规

波特五力：驾驭人类胚胎干细胞市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势、解决弱点并避免潜在的挑战，以确保更强大的市场地位。

PESTLE分析：了解外部对人类胚胎干细胞市场的影响

外部宏观环境因素在塑造人类胚胎干细胞市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解人类胚胎干细胞市场的竞争状况

人类胚胎干细胞市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵人类胚胎干细胞市场供应商的绩效评估

FPNV定位矩阵是评估人类胚胎干细胞市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了人类胚胎干细胞市场的成功之路

人类胚胎干细胞市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 遗传病患病率迅速增加
      • 消费者越来越意识到干细胞治疗疾病的有效性
      • 对再生医学的需求不断增加
    • 抑制因素
      • 治疗费用高
    • 机会
      • 人类胚胎干细胞正在进行的研究活动
      • 干细胞治疗技术发展
    • 任务
      • 严格的政府规章制度
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 人类胚胎干细胞市场：依类型

  • 多功能细胞
  • 全能干细胞
  • 单能干细胞

第七章 人类胚胎干细胞市场：依应用分类

  • 再生医学
  • 干细胞生物学研究
  • 组织工程
  • 毒性试验

第八章 人类胚胎干细胞市场：依最终用户分类

  • 临床试验
  • 调查

第九章美洲人类胚胎干细胞市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区人类胚胎干细胞市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲人胚胎干细胞市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Astellas Pharma Inc.
  • Becton, Dickinson and Company
  • Biotime, Inc
  • CellGenix GmbH
  • International Stem Cell Corporation
  • Lineage Cell Therapeutics Inc.
  • Lonza Group AG
  • Merck KGaA
  • Novo Nordisk A/S
  • PeproTech Inc.
  • Pfizer Inc.
  • PromoCell GmbH
  • Qiagen NV
  • R&D Systems, Inc.
  • Smith & Nephew PLC
  • Stemcell Technologies Inc.
  • Sumanas, Inc.
  • Takara Bio Inc.
  • Thermo Fisher Scientific, Inc.
  • ViaCyte, Inc.
Product Code: MRR-AD36CD897E4B

The Human Embryonic Stem Cells Market was valued at USD 848.35 million in 2023, expected to reach USD 920.43 million in 2024, and is projected to grow at a CAGR of 8.98%, to USD 1,549.81 million by 2030.

Human Embryonic Stem Cells (hESCs) are pluripotent stem cells derived from early-stage human embryos capable of differentiating into any cell type. Their unique properties make them pivotal in regenerative medicine, drug discovery, and developmental biology. The necessity of hESCs lies in their potential to revolutionize disease treatment, particularly in conditions like Parkinson's, diabetes, and heart diseases, where they can help regenerate damaged tissues. Applications extend to toxicology testing, genetic research, and personalized medicine, as these cells offer patient-specific therapy avenues. End-users encompass institutes focusing on stem cell research, biotechnology companies, and clinical research organizations. Key growth drivers include advancements in regenerative medicine, increasing government and private funding for stem cell research, and rising prevalence of chronic diseases demanding innovative treatment solutions. Additionally, the growing interest in precision medicine opens lucrative opportunities for hESC-based therapies. However, ethical concerns surrounding the source of hESCs and regulatory hurdles present significant challenges. Technological limitations in controlling stem cell differentiation and high costs involved in hESC-based treatments also impede market growth. Opportunities exist in overcoming these challenges by developing ethical sourcing methods, enhancing differentiation techniques, and reducing production costs, thus widening the acceptance and application of hESCs. The market also holds potential in collaborations for technology sharing and increasing public awareness regarding stem cell benefits. With the growing demand for advanced therapeutic solutions, innovation is critical. Focus areas should include genetic engineering to improve cell therapies, upscaling manufacturing for broader access, and improving bioinformatics for better disease modeling. The hESC market is dynamic and poised for substantial growth as stakeholders address ethical and regulatory issues, create innovative solutions, and adapt to the evolving demand for personalized medicine and regenerative therapies.

KEY MARKET STATISTICS
Base Year [2023] USD 848.35 million
Estimated Year [2024] USD 920.43 million
Forecast Year [2030] USD 1,549.81 million
CAGR (%) 8.98%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Human Embryonic Stem Cells Market

The Human Embryonic Stem Cells Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Surge in the prevalence of genetic disorders
    • Growing awareness among consumers about the stem cell therapeutic potency for disease treatment
    • Increasing demand for the regenerative medicines
  • Market Restraints
    • High cost of treatment
  • Market Opportunities
    • Ongoing research activities in the human embryonic stem cells
    • Technological development in the stem cell therapy
  • Market Challenges
    • Strict rules and regulations of the government

Porter's Five Forces: A Strategic Tool for Navigating the Human Embryonic Stem Cells Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Human Embryonic Stem Cells Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Human Embryonic Stem Cells Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Human Embryonic Stem Cells Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Human Embryonic Stem Cells Market

A detailed market share analysis in the Human Embryonic Stem Cells Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Human Embryonic Stem Cells Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Human Embryonic Stem Cells Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Human Embryonic Stem Cells Market

A strategic analysis of the Human Embryonic Stem Cells Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Human Embryonic Stem Cells Market, highlighting leading vendors and their innovative profiles. These include Astellas Pharma Inc., Becton, Dickinson and Company, Biotime, Inc, CellGenix GmbH, International Stem Cell Corporation, Lineage Cell Therapeutics Inc., Lonza Group AG, Merck KGaA, Novo Nordisk A/S, PeproTech Inc., Pfizer Inc., PromoCell GmbH, Qiagen NV, R&D Systems, Inc., Smith & Nephew PLC, Stemcell Technologies Inc., Sumanas, Inc., Takara Bio Inc., Thermo Fisher Scientific, Inc., and ViaCyte, Inc..

Market Segmentation & Coverage

This research report categorizes the Human Embryonic Stem Cells Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Pluripotent Stem Cells, Totipotent Stem Cells, and Unipotent Stem Cells.
  • Based on Application, market is studied across Regenerative Medicine, Stem Cell Biology Research, Tissue Engineering, and Toxicology Testing.
  • Based on End-User, market is studied across Clinical Trials and Research.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Surge in the prevalence of genetic disorders
      • 5.1.1.2. Growing awareness among consumers about the stem cell therapeutic potency for disease treatment
      • 5.1.1.3. Increasing demand for the regenerative medicines
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research activities in the human embryonic stem cells
      • 5.1.3.2. Technological development in the stem cell therapy
    • 5.1.4. Challenges
      • 5.1.4.1. Strict rules and regulations of the government
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Human Embryonic Stem Cells Market, by Type

  • 6.1. Introduction
  • 6.2. Pluripotent Stem Cells
  • 6.3. Totipotent Stem Cells
  • 6.4. Unipotent Stem Cells

7. Human Embryonic Stem Cells Market, by Application

  • 7.1. Introduction
  • 7.2. Regenerative Medicine
  • 7.3. Stem Cell Biology Research
  • 7.4. Tissue Engineering
  • 7.5. Toxicology Testing

8. Human Embryonic Stem Cells Market, by End-User

  • 8.1. Introduction
  • 8.2. Clinical Trials
  • 8.3. Research

9. Americas Human Embryonic Stem Cells Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Human Embryonic Stem Cells Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Human Embryonic Stem Cells Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Astellas Pharma Inc.
  • 2. Becton, Dickinson and Company
  • 3. Biotime, Inc
  • 4. CellGenix GmbH
  • 5. International Stem Cell Corporation
  • 6. Lineage Cell Therapeutics Inc.
  • 7. Lonza Group AG
  • 8. Merck KGaA
  • 9. Novo Nordisk A/S
  • 10. PeproTech Inc.
  • 11. Pfizer Inc.
  • 12. PromoCell GmbH
  • 13. Qiagen NV
  • 14. R&D Systems, Inc.
  • 15. Smith & Nephew PLC
  • 16. Stemcell Technologies Inc.
  • 17. Sumanas, Inc.
  • 18. Takara Bio Inc.
  • 19. Thermo Fisher Scientific, Inc.
  • 20. ViaCyte, Inc.

LIST OF FIGURES

  • FIGURE 1. HUMAN EMBRYONIC STEM CELLS MARKET RESEARCH PROCESS
  • FIGURE 2. HUMAN EMBRYONIC STEM CELLS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. HUMAN EMBRYONIC STEM CELLS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. HUMAN EMBRYONIC STEM CELLS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HUMAN EMBRYONIC STEM CELLS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HUMAN EMBRYONIC STEM CELLS MARKET DYNAMICS
  • TABLE 7. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY PLURIPOTENT STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TOTIPOTENT STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY UNIPOTENT STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY STEM CELL BIOLOGY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TISSUE ENGINEERING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TOXICOLOGY TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. HUMAN EMBRYONIC STEM CELLS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. HUMAN EMBRYONIC STEM CELLS MARKET, FPNV POSITIONING MATRIX, 2023